<DOC>
	<DOCNO>NCT01752023</DOCNO>
	<brief_summary>Response rate . Changes tumor blood flow .</brief_summary>
	<brief_title>A Randomized Phase II Study SUBATM-itraconazole Patients With Untreated Squamous NSCLC .</brief_title>
	<detailed_description>To determine objective response rate cisplatin gemcitabine without SUBATM-itraconazole patient chemotherapy-na√Øve metastatic squamous non-small cell lung cancer . To assess change tumor blood flow measure contrast enhance MRI scan patient metastatic squamous non-small cell lung cancer treat cisplatin gemcitabine without SUBATM-itraconazole .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Stage IV squamous cell lung cancer , prior systemic chemotherapy . Patients receive prior adjuvant chemotherapy earlystage lung cancer eligible least 6 month elapse completion treatment . Patients whose tumor contain mixed nonsmall cell histology eligible squamous carcinoma predominant histology . Mixed tumor small cell anaplastic element eligible . Patient must measurable disease per RECIST 1.1 ( define section 9.1.2 ) . Patients previous radiotherapy definitive therapy locally advance nonsmall cell lung cancer eligible , long recurrence outside original radiation therapy port . Radiation therapy must complete great equal 2 week prior enroll study . Age great equal 18 year . Because dose adverse event data currently available use itraconazole SUBATMitraconazole combination gemcitabine/cisplatin patient 18 year age , patient exclude study . Squamous cell lung cancer exceedingly rare child . Life expectancy least 12 week . Eastern Cooperative Oncology Group performance status 0 1 . Patients must adequate organ marrow function . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document . Prior treatment gemcitabine , cisplatin ( except adjuvant setting ) , itraconazole SUBATMitraconazole . Uncontrolled brain metastasis . Patients brain metastasis must stable neurologic status follow local therapy ( surgery radiation ) least 2 week , must without neurologic dysfunction would confound evaluation neurologic adverse event . History allergic reaction attribute compound similar chemical biologic composition itraconazole , SUBATMitraconazole , gemcitabine , cisplatin agent use study . Itraconazole strong CYP3A4 inhibitor may increase plasma concentration drug metabolize pathway . Coadministration cisapride , midazolam , pimozide , quinidine , lovastatin , simvastatin , triazolam , dofetilide , levacetylmethadol ( levomethadyl ) SUBATMitraconazole itraconazole contraindicate . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study itraconazole Class C agent gemcitabine cisplatin Class D agent , potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother SUBATMitraconazole gemcitabine/cisplatin , breastfeed discontinue mother treat protocol . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction SUBATMitraconazole , gemcitabine , cisplatin essential mediation . Medical contraindication MRI ( e.g . gadolinium allergy , severe claustrophobia ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>